银屑病关节炎中b/tsDMARD停药与治疗反应的预测因素:英国风湿病学会银屑病关节炎登记研究
中位暴露31个月时65%仍在用原药,停药主因无效(55%)或不耐受(26%);PDE4抑制剂停药风险是TNF抑制剂2.25倍(95%CI 1.45-3.50)。12个月时24%达MDA、24%达ACR50、49%达PsARC,男性、年轻及在职者更易应答。
要点
- PDE4抑制剂停药风险显著高于TNF抑制剂(HR 2.25,95%CI 1.45-3.50)。
- 12个月MDA、ACR50、PsARC达标率分别为24%、24%、49%。
- 男性、年轻及在职者更可能获得治疗反应。
核心结论
- PsA中b/tsDMARD治疗持久性和反应仍不理想,受人口学因素和基线疾病严重程度显著影响。
- PDE4抑制剂较TNF抑制剂停药风险更高,其他作用机制间无重大差异。
研究设计与样本
- 治疗起始时收集临床和患者报告指标,采用Cox回归(多重插补 predictive mean matching处理缺失)识别停药预测因素,logistic回归识别12个月MDA、ACR50和PsARC反应预测因素。
主要发现
- 截至2025年8月1日删失时,65%仍在原药治疗(中位暴露31个月),停药主要因无效(55%)或不耐受(26%)。
- 12个月时24%达MDA、24%达ACR50、49%达PsARC。
- 基于插补结局,男性、较年轻及在职者更一致地更可能获得治疗反应,较差的基线临床或患者报告指标预测无反应。
关键数值与推荐
- PDE4抑制剂起始者停药风险是TNF抑制剂起始者的2.25倍(HR 2.25;95%CI 1.45-3.50)。
- 其他作用机制间未观察到重大差异。
临床怎么用
- 临床选择b/tsDMARD时需考虑PDE4抑制剂较高停药风险,尤其对TNF抑制剂适用者。
- 对男性、年轻、在职及基线指标较好者预期反应更佳,可辅助风险分层。
- 基线疾病活动度高及患者报告指标差者应加强监测和预期管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Despite advances in biologic and targeted synthetic DMARDs (b/tsDMARDs), many patients with psoriatic arthritis (PsA) experience suboptimal responses and discontinue therapy. We aimed, in a real-world registry, to identify predictors of b/tsDMARD discontinuation and treatment response. METHODS: Patients commencing b/tsDMARD therapy were identified from the British Society for Rheumatology Psoriatic Arthritis Register (BSR‑PsA). Clinical and patient‑reported measures were collected at treatment start. Cox regression identified predictors of drug discontinuation using multiple imputation with predictive mean matching to handle missing data, and logistic regression identified predictors of achieving 12-month Minimal Disease Activity (MDA), ACR50 and PsARC response. RESULTS: Eight-hundred and fifteen participants were included; 40% male, median age 51 years, with high disease activity (median DAPSA 33.5; PASDAS 5.9). At censoring (01‑Aug‑2025), 65% remained on their index therapy (median exposure 31 months) with discontinuation primarily due to inefficacy (55%) or intolerance (26%). Patients commencing PDE4 inhibition experienced more than a doubling in the risk of discontinuation, compared to those starting TNF inhibitors (Hazard Ratio: 2.25; 95%CI: 1.45-3.50), while no major differences were observed with other modes of action. At 12-months, 24% achieved MDA, 24% ACR50, and 49% PsARC. Based on imputed outcomes, men, younger individuals, and those who were employed were consistently more likely to achieve treatment response, while poorer baseline clinical or patient‑reported measures predicted non‑response. CONCLUSIONS: Treatment persistence and response in PsA remain a problem and are strongly influenced by demographic factors and baseline disease severity. A better understanding of predictors of non-response may aid future risk stratification.
引用
- Rotariu, Lembke, Helliwell, et al. Predictors of b/tsDMARDs discontinuation and treatment response in psoriatic arthritis: results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR-PsA). Rheumatology (Oxford). 2026. PMID: 42937132. doi:10.1093/rheumatology/keag598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。